NEW YORK--(BUSINESS WIRE)--WallStreet Research™ (WSR), a top-ranked independent research firm with a history spanning over three decades, today announced that it has initiated Corporate Profile coverage on Nemaura Medical, Inc. (OTCQB: NMRD) (the “Company”). WallStreet Research™ is ranked Number One on the Google, Yahoo, and Bing search engines for both small and micro-cap research with a global following. A Corporate Profile Report, together with additional information about WallStreet Research™, is available at the www.WallStreetResearch.org website. The WSR Corporate Profile highlights the Company’s recent accomplishments and growth plans for 2017 and beyond.
Nemaura Medical Inc. (OTCQB:NMRD) is a medical technology company based in Loughborough Science Park in the United Kingdom (incorporated in Nevada) developing sugarBEAT® as a patent protected non-invasive, affordable and flexible glucose monitoring system. European clinical trials for sugarBEAT® are expected to be completed by end of November 2017, with product launch anticipated shortly afterwards in the United Kingdom.
SugarBEAT® consists of a disposable adhesive skin-patch connected to a rechargeable transmitter, with an app displaying glucose readings, and is expected to empower both type I and type II diabetics to better manage glucose levels, thereby helping prevent or delay long term medical complications.
The Company’s underlying BEAT technology platform has the potential to transform health monitoring by providing non-invasive feedback on analytes including amino acid, oxygen, lactate and a range of prescription medicines.
Mr. Alan Stone, Managing Director of WallStreet Research™ commented, “The European Diabetes device market consists of approximately 31 million people living with diabetes, and this market is expected to grow significantly in the coming decade. We believe that Nemaura Medical is well positioned to soon penetrate this market with a well designed alternative new technology.”
On August 9, 2017, the Company reported First Quarter 2017 financial results for the period ending June 30. Research and Development expenses fell to $149,198 for the quarter ended June 2017, a decrease of 51% from $306,081 for the same quarter in 2016. This decrease of $156,883 is due to sugarBEAT® product development nearing completion. General and Administrative expenses increased to $268,122 for the quarter ended June 2017, compared to $188,102 for same quarter in 2016. The Company’s Comprehensive Loss fell to $205,032 for the three months ended June 30, 2017, a decrease of 80% from $1,024,198 for the same quarter in 2016. As of June 30, 2017, the Company’s combined cash and bank deposits (short and long- term) were $7,111,493.
Information on WallStreet Research™ can be found at www.WallStreetResearch.org.
About Nemaura Medical Inc.
Nemaura Medical Inc. (OTCQB: NMRD), is a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible glucose monitoring system for adjunctive use by diabetics. SugarBEAT® consists of a disposable adhesive skin-patch connected to a rechargeable transmitter, with an app displaying glucose readings. For more information, please visit www.NemauraMedical.com and www.SugarBEAT.com.
Cautionary Statement Regarding Forward Looking Statements
The statements in this press release that are not historical facts, and may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Nemaura Medical’s ongoing studies, including the safety and efficacy of Nemaura Medical’s sugarBEAT® CGM system, the failure of future development and preliminary marketing efforts, Nemaura Medical’s ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Nemaura Medical and its partners’ ability to develop, market and sell sugarBEAT®, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to sugarBEAT®. These and other risks and uncertainties are identified and described in more detail in Nemaura Medical’s filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the current year, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Nemaura Medical undertakes no obligation to publicly update or revise any forward-looking statements.
About WallStreet Research™
WallStreet Research™ (“WSR”) is a prominent research boutique led by Mr. Alan Stone, Managing Director of Alan Stone & Company, LLC (ASC). The firm specializes in the micro-cap and small cap investment arena, looking for emerging growth companies with strong management, unique or proprietary technology, significant market potential, financial strength, and outstanding long-term earnings growth possibilities. The firm has offices in Los Angeles, CA; Palm Beach, FL; and New York City, NY, and is well known for discovering undervalued companies and bringing them to the attention of the investment community. ASC/WSR also arranges road shows for its publicly traded clients, before the investment community in New York City, California, Nevada, and Florida. www.WallStreetResearch.org.
Wall Street Research Disclaimer
The information presented in the corporate file by WSR is not to be construed as an offer to sell, nor a solicitation of an offer to purchase, any securities of NMRD. The corporate profile by Wall Street Research is not a research report, but a compilation of publicly available information, which has been furnished by NMRD or gathered from other sources, in each case without independent verification, and no representations are made as to the accuracy or validity thereof. The information may include certain forward-looking statements within the meaning of Section 21E of the Securities Exchange Commission Act of 1934, which may be affected by unforeseen circumstances or certain risks. Any investment in securities contains inherent risks and should only be done after consulting an investment professional. NMRD paid a fee of $7500 in cash to Alan Stone & Company LLC for preparation and distribution of the corporate profile. For complete disclaimer information, readers are hereby referred to the Disclaimer Page at the www.WallStreetResearch.org website.